Studies indicated that the risk increased with higher cumulative doses and longer duration of use (specifically more than 12 months).
In 2011, the FDA issued a safety communication warning about these risks. Around the same time, countries like France and Germany suspended or restricted the use of the drug. ACTOS CANCER
In 2015, Takeda Pharmaceuticals agreed to a massive $2.37 billion settlement to resolve approximately 9,000 bladder cancer claims in the U.S.. Studies indicated that the risk increased with higher
While the drug remains on the market in the U.S., the FDA prescribing information now includes warnings about the potential bladder cancer risk. 3. Warning Signs and Symptoms ACTOS CANCER